IcoSema and the evolution of fixed-ratio insulin–GLP-1 receptor agonist therapies Once-daily fixed-ratio combination therapies of basal insulin and a GLP-1 receptor agonist such as insulin degludec with liraglutide (IDegLira) and insulin glargine U100 with lixisenatide (IGlarLixi) ...

Also read the joint Linked Comment on both papers:
#IcoSema and the evolution of fixed-ratio insulin–GLP-1 receptor agonist therapies thelancet.com/journals/lan... #T2D

#MedSky #EndoSky

Once-weekly IcoSema versus multiple daily insulin injections in type 2 diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial Once-weekly IcoSema achieved non-inferior HbA1c reduction and superiority in change in bodyweight, weekly total insulin dose, and hypoglycaemia rates versus daily BBT, suggesting that there is a poten...

New—Once-weekly #IcoSema versus multiple daily #insulin injections in type 2 #diabetes management (COMBINE 3): an open-label, multicentre, treat-to-target, non-inferiority, randomised, phase 3a trial thelancet.com/journals/lan... #T2D

#MedSky #EndoSky

Once‑weekly IcoSema versus once‑weekly insulin icodec in type 2 diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial In adults with inadequately controlled type 2 diabetes on daily basal insulin therapy, once‑weekly IcoSema showed superiority to once-weekly icodec alone in changes in HbA1c and in overall lower rate ...

New—Once‑weekly #IcoSema versus once‑weekly #insulin #icodec in type 2 #diabetes management (COMBINE 1): an open‑label, multicentre, treat‑to‑target, randomised, phase 3a trial thelancet.com/journals/lan... #T2D

#MedSky #EndoSky

A graph displaying the change in HbA1c levels over 52 weeks for IcoSema (dark blue) and Semaglutide 1.0 mg (light blue). The graph shows a greater reduction in HbA1c for IcoSema (-14.7 mmol/mol) compared to Semaglutide (-9.88 mmol/mol). The x-axis represents time in weeks (0 to 52), and the y-axis represents the change in HbA1c (mmol/mol). Data points with error bars indicate the trend of decreasing HbA1c levels over time, with IcoSema showing a steeper decline. A water droplet icon highlights the estimated mean change for each treatment.

A graph depicting the change in fasting blood glucose (FPG) levels over 52 weeks for IcoSema (dark blue) and Semaglutide 1.0 mg (light blue). IcoSema results in a greater reduction in FPG (-2.48 mmol/l) compared to Semaglutide (-1.43 mmol/l). The x-axis represents time in weeks (0 to 52), and the y-axis shows the change in FPG (mmol/l). Both treatments show an initial decline, with IcoSema achieving a steeper and more sustained reduction. A glucose monitor icon represents the estimated mean change for each treatment.

A graph illustrating the change in body weight over 52 weeks for IcoSema (dark blue) and Semaglutide 1.0 mg (light blue). Semaglutide leads to a significant weight reduction (-3.70 kg), while IcoSema results in a slight weight gain (+0.84 kg). The x-axis represents time in weeks (0 to 52), and the y-axis indicates the change in body weight (kg). The Semaglutide group shows a steady decrease in weight, while the IcoSema group experiences a slight increase. A scale icon with footprints visually represents the weight change for each treatment.

📊A recent phase III trial shows superior #glycaemic control with #IcoSema vs #Semaglutide.

“IcoSema provides a good balance between efficacy and safety while also reducing the total number of injections in a year,” the study authors write.

📰Read more👉 easd-elearning.eu/index.html@p...

#Diabetes

Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial - Diabetologia Aims/hypothesis COMBINE 2 assessed the efficacy and safety of once-weekly IcoSema (a combination therapy of basal insulin icodec and semaglutide) vs once-weekly semaglutide (a glucagon-like peptide-1 ...

In adults with #T2D in #COMBINE_2, #once-weekly #IcoSema, a combination of #icodec and #semaglutide, led to superior reduction in HbA1c after 52 wks vs once-weekly #semaglutide, with similar #hypoglycaemia rates, but weight change favoured semaglutide tinyurl.com/b3uwndny 🔓